Spark Therapeutics reported a net loss of $65 million, or $1.90 per share, for the third quarter of 2017 compared with a net loss of $32.6 million, or $1.07 per share, for the same period of 2016.
Revenue rose from $1.3 million in 2016’s third quarter to $1.9 million in 2017’s third quarter, according to a press release.
Research and development costs rose from $22.4 million a year ago to $39.3 million.
General and administrative expenses were $26.6 million compared with $12 million in 2016, an increase attributed to a (Read more...)
Uncategorized